Innovative Metastatic Breast Cancer Treatment Halaven® (Eribulin) Recieves Reimbursement Approval in the Czech Republic

Innovative Metastatic Breast CancerInnovative Metastatic Breast Cancer Treatment Halaven® (Eribulin) Recieves Reimbursement Approval in the Czech Republic PR Newswire HATFIELD, England, January 6, 2014 ®Halaven (eribulin) has received reimbursement approval in the Czech Republic as a highly innovative drug for patients with metastatic breast cancer, effective from the 1 January 2014. Eribulin is the first, single-agent chemotherapy to demonstrate a prolonged overall survival in patients with heavily pre-treated advanced breast cancer, compared to other single agent [1]chemotherapies. "The reimbursement of eribulin in the Czech Republic is an important step forward for women with metastatic breast cancer," says Professor MUDr. Bohuslav Melichar, PhD, the Scientific Secretary of the Czech Society for Oncology. "These patients urgently need new treatment options and in particular, therapies which have demonstrated an overall survival benefit in heavily pre-treated patients. The advent of eribulin will be welcomed by patients and doctors across the country." Breast cancer is the most common cancer in Czech women and accounts for nearly 25% of all newly diagnosed malignancies in the female [2]population. More than 6,400 people are diagnosed with breast cancer [3]each year in the Czech Republic and metastatic disease will develop in approximately 30% of cases. "Metastatic breast cancer continues to affect many women across Europe.